Myriad Genetics has received clearance from the U.S. Food and Drug Administration (FDA) for use of its myChoice CDx test for identifying advanced ovarian cancer in patients with positive homologous recombination deficiency status.
The clearance allows clinicians to use the test in women who are eligible for treatment with olaparib (Lynparza, Merck/AstraZeneca) in combination with bevacizumab (Avastin, Roche), the company said. Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor developed by AstraZeneca and Merck; Myriad has been collaborating with AstraZeneca since 2007 to develop companion diagnostics for Lynparza, according to the firm.
